Table 2.

Summary of results from subgroup and sensitivity analyses

	SGLT2 inhibitor vs. DPP-4 inhibitor			SGLT2 inhibitor vs. sulfonylurea
Sensitivity analysis	SGLT2 inhibitor, n	DPP-4 inhibitor, n	aHR (95% CI)	SGLT2 inhibitor, n	Sulfonylurea, n	aHR (95% CI)
Increasing permissible grace period between consecutive refills from 30 to 60 days	85,125	85,125	1.77 (1.48, 2.12)	72,436	72,436	1.60 (1.34, 1.92)
Increasing permissible grace period between consecutive refills from 30 to 60 days	85,125	85,125	1.78 (1.49, 2.13)	72,436	72,436	1.62 (1.35, 1.94)
Trimming PS distribution tail to 95th and 5th percentile	84,992	84,992	1.62 (1.34, 1.94)	71,592	71,592	1.56 (1.30, 1.87)
Trimming PS distribution tail to 85th and 15th percentile	79,510	79,510	1.67 (1.38, 2.02)	58,495	58,495	1.45 (1.20, 1.76)
Trimming PS distribution tail to 75th and 25th percentile	63,126	63,126	1.67 (1.35, 2.05)	39,063	39,063	1.49 (1.20, 1.85)
Adjusting for PS in the primary outcome model	100,046	212,311	1.53 (1.29, 1.84)	84,583	296,947	1.47 (1.18, 1.82)
Limiting the study period to 2015	26,333	26,333	1.26 (1.02, 1.57)	22,968	22,968	1.53 (1.21, 1.93)